Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,841 across all filing types
Latest filing 2026-05-25 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
关于因权益分派调整健帆转债转股价格的公告
Capital/Financing Update Classification · 85% confidence The document is a formal corporate announcement by the board of 健帆生物科技集团股份有限公司 informing investors of an adjustment to the conversion price of its outstanding convertible bonds (“健帆转债”) due to the 2025 profit distribution (cash dividend). It details the legal basis, adjustment formulas, historical adjustments, and the effective date. This is not a routine financial report or proxy statement but a change in the terms of a financing instrument, impacting the company’s capital structure. Therefore, it falls under a Capital/Financing Update (CAP).
2026-05-25 Chinese
2025年度权益分派实施公告
Notice of Dividend Amount Classification · 90% confidence The document is a company announcement detailing the 2025 profit distribution (cash dividend per 10 shares, record date, ex-dividend date, tax treatment, total amount, implementation method, etc.). This matches a Notice of Dividend Amount, not a full financial report or other regulatory filing. Therefore, it should be classified as DIV.
2026-05-25 Chinese
关于实施权益分派期间健帆转债暂停转股的公告
Capital/Financing Update Classification · 80% confidence The document is an official announcement by the company concerning the suspension of conversion rights of its convertible bonds (“健帆转债”) during the equity distribution record period. This relates directly to the company’s financing instruments and a temporary change to its capital structure. It is not a report of financial results, board changes, or a regulatory certification, but a corporate financing update about convertible bond conversion rights. Therefore, it falls under Capital/Financing Update.
2026-05-21 Chinese
第六届董事会第一次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of the resolutions passed at the first meeting of the sixth board of directors of the company. It details the election of the board chairman, appointment of various senior management positions including president, vice presidents, board secretary, and financial director. It includes voting results and references to related announcements on a regulatory disclosure website. There are no financial statements or detailed financial performance data. The content focuses on board and senior management changes. Therefore, this document fits the category of Board/Management Information (MANG). The document length is 2620 characters, which is consistent with a detailed announcement but not a full report like an annual or interim report.
2026-05-19 Chinese
2025年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2025 Annual General Meeting (AGM) of 健帆生物科技集团股份有限公司. It includes information about the meeting date, attendance, voting results on various proposals including the annual report, board work report, profit distribution plan, auditor appointment, remuneration plans, and election of board members. It also contains legal opinions confirming the validity of the meeting and resolutions. The content is focused on the official voting results and decisions made at the AGM rather than the full annual report or financial statements themselves. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (6227 characters) and detailed voting data support this classification rather than a brief announcement or a full report.
2026-05-19 Chinese
国浩律师（深圳）事务所关于公司2025年度股东会之法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2025 Annual General Meeting (AGM) of the company. It details the procedures of the AGM, the qualifications of attendees, the voting process, and the voting results on various resolutions including approval of the 2025 Annual Report, board reports, profit distribution plans, auditor reappointment, remuneration plans, and election of directors. The document is not the Annual Report itself but a legal opinion on the AGM proceedings and resolutions. It includes detailed voting results and confirms the legality and validity of the AGM decisions. This type of document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting outcomes of the shareholder meeting. The document length (8017 characters) and content confirm it is not a brief announcement or a report publication notice but a substantive legal opinion on the AGM and voting results. Therefore, the correct classification is DVA with high confidence.
2026-05-19 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.